News
Keensight Capital invests in AstraZeneca spin-out
Keensight Capital has invested in CatSci – a contract research organisation (CRO) that supports leading pharma companies to deliver life-changing therapeutics to patients around the world.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Keensight Capital has invested in CatSci – a contract research organisation (CRO) that supports leading pharma companies to deliver life-changing therapeutics to patients around the world.